Global Longitudinal Strain Provides Superior Prognostic Information Compared to Ejection Fraction
Global longitudinal strain (GLS) has greater prognostic value than ejection fraction (EF) for predicting mortality and clinical outcomes across multiple cardiac conditions, and should be prioritized for risk stratification in clinical practice.
Evidence Supporting GLS Superiority
The most compelling evidence comes from multiple high-quality guidelines and recent research demonstrating GLS outperforms EF:
In Heart Failure Populations
GLS consistently predicts mortality better than LVEF in heart failure patients. In a landmark study of 4,172 consecutive acute heart failure patients, each 1% increase in GLS was associated with a 5% decreased risk for mortality (p<0.001), while LVEF was not independently associated with mortality in multivariable analysis 1. This finding held across all EF categories—reduced, midrange, and preserved ejection fraction.
A dedicated heart failure with reduced ejection fraction (HFrEF) study of 1,065 patients confirmed GLS as an independent predictor of all-cause mortality (HR: 1.15 per 1% decrease, p=0.008) after adjusting for all conventional echocardiographic parameters, including EF 2. Critically, GLS had the highest C-statistics of all echocardiographic parameters and added significant incremental prognostic value through net reclassification improvement (p=0.009).
Guideline Recognition
The 2021 EACVI multimodality imaging consensus explicitly states that "2D and 3D speckle tracking-derived global longitudinal strain can detect systolic dysfunction earlier than LVEF and provides additional prognostic information in a wide range of myocardial diseases" 3.
The 2017 EACVI/ASE aortic stenosis guidelines acknowledge that "GLS measurements in severe AS may detect impairment of LV systolic function when EF is still normal and may predict prognosis" 4, though they note limitations require further validation in asymptomatic patients.
Across Different Clinical Contexts
In sepsis/septic shock: A 2026 meta-analysis of 9 cohort studies demonstrated LVGLS was significantly more impaired in non-survivors (SMD -0.40,95% CI -0.62 to -0.18), while LVEF showed no association with short-term mortality (SMD 0.06,95% CI -0.08 to 0.20) 5.
In heart transplant recipients: GLS detected subtle graft dysfunction and correlated with rejection grades despite stable LVEF 6, 7, with one study showing GLS as an independent predictor of 1-year mortality 6.
In general populations: A foundational 2009 study of 546 consecutive patients showed GLS was superior to both EF and wall motion score index for predicting 5-year mortality, with the greatest increment in model power (chi²=34.9, p<0.001) 8.
Clinical Thresholds and Interpretation
Prognostic Cut-offs
- GLS ≤-12% is equivalent to EF ≤35% for predicting prognosis 8
- GLS >-16% indicates mild depression 9
- GLS <-10% indicates severe reduction 9
- GLS >-12.6% defines mildly reduced strain with 34% 5-year mortality
- GLS 8.1-12.5% defines moderately reduced strain with 38% mortality
- GLS ≤8.0% defines severely reduced strain with 49% mortality 1
In asymptomatic stable heart failure, GLS <-9.0% predicted clinical progression with 88.5% sensitivity and specificity (AUC: 0.883), vastly outperforming EF <42% (AUC: 0.654, sensitivity 70.4%, specificity 54%) 10.
Important Caveats and Limitations
When GLS May Be Less Useful
In advanced heart failure: Automated cluster analysis of HFrEF patients showed GLS lost independent prognostic value in the highest-risk phenogroup (severe diastolic dysfunction, pulmonary hypertension, RV dysfunction) where outcome was already determined by other factors 11.
Atrial fibrillation modifies the relationship: GLS had stronger prognostic value in patients without AF (HR: 1.22 per 1% decrease) compared to those with AF (HR: 1.08, p for interaction=0.036) 2.
Sex differences exist: GLS was a stronger predictor in men (HR: 1.23 per 1% decrease, p<0.001) than women (HR: 1.09, p=0.083) 2.
Technical Limitations
The 2017 EACVI/ASE guidelines caution about inter-vendor differences in strain measurements and afterload dependence 4. The 2023 ACC HFpEF consensus notes GLS ranges from -18% to -22% in healthy persons, acknowledging vendor variability 12.
Practical Implementation Algorithm
For risk stratification in any patient with suspected or known cardiac dysfunction:
Obtain both LVEF and GLS on routine echocardiography 13
Prioritize GLS for prognostication when:
- LVEF is preserved (≥50%) but clinical suspicion for dysfunction exists
- Patient is asymptomatic but has known heart failure
- Assessing response to therapy or disease progression
- Evaluating septic shock patients for cardiac dysfunction
Use GLS thresholds for risk stratification:
- GLS >-16%: Consider intensified monitoring/treatment
- GLS >-12%: High-risk, equivalent to severely reduced EF
- GLS >-9%: Very high risk in stable HF, warrants intervention
Interpret with caution in:
- Advanced heart failure with multiple high-risk features (rely on comprehensive assessment)
- Atrial fibrillation (reduced but still present prognostic value)
- Immediately post-cardiac surgery (paradoxical septal motion affects regional strain)
The 2025 ESICM shock guidelines and 2025 ESC advanced heart failure imaging consensus both acknowledge GLS may have prognostic significance beyond EF 14, 15, supporting its integration into routine clinical assessment.
The evidence overwhelmingly demonstrates GLS provides incremental and often superior prognostic information compared to EF alone, detecting subclinical dysfunction earlier and predicting outcomes more accurately across diverse cardiac conditions.